title: Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment.
abstract: The aim of this study was to determine the correlation between dynamic changes in serum cytokine/chemokine expression levels in response to entecavir (ETV) treatment and HBV e antigen (HBeAg) seroconversion in patients with chronic hepatitis B (CHB). Four cytokines (interleukin [IL]-4, IL-6, IL-8, and interferon-γ) and five chemokines (macro-phage inflammatory protein [MIP]-1α, MIP-1β, platelet derived growth factor-BB, and interferon-inducible protein 10 [IP-10]) before ETV therapy and at 3, 6, 12, 24, 36 and 60 months during therapy in 105 CHB patients were analyzed. The results showed that the low decrease rate of IP-10 levels after 1 year of ETV treatment was an independent predictor of HBeAg seroconversion at year 5 (Hazard ratio = 0.972). The area under the receiver operating characteristic curves for the decrease rate of IP-10 levels after 1 year of treatment to discriminate a year-5 HBeAg seroconversion was 0.752 (p = 0.005). The results indicate that higher IP-10 level at year one of ETV treatment is associated with an increased probability of HBeAg seroconversion. Quantification of IP-10 during ETV treatment may help to predict long-term HBeAg seroconversion in patients with CHB.
authors.affiliation: Department of Laboratory Medicine, First Affiliated Hospital, College of Medicine, Zhejiang University; Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, Hangzhou, China.
authors.forename: Renyong
authors.initials: R
authors.lastname: Guo
authors.affiliation: Maternity and Child Health Care Hospital of Xiacheng District, Hangzhou, China.
authors.forename: Hejun
authors.initials: H
authors.lastname: Mao
authors.affiliation: Department of Laboratory Medicine, First Affiliated Hospital, College of Medicine, Zhejiang University; Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, Hangzhou, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Hu
authors.affiliation: Department of Gynecology and Obstetrics, Tongde Hospital of Zhejiang Province, Hangzhou, China.
authors.forename: Nengneng
authors.initials: N
authors.lastname: Zheng
authors.affiliation: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases; First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Dong
authors.initials: D
authors.lastname: Yan
authors.affiliation: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases; First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Jianqin
authors.initials: J
authors.lastname: He
authors.affiliation: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases; First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Jiezuan
authors.initials: J
authors.lastname: Yang
mesh_terms: D000328:Adult; D054357:Chemokine CXCL10 / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006513:Hepatitis B e Antigens / Q000097:blood*; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069078:Seroconversion; D013997:Time Factors
chemical_list: C114753:CXCL10 protein, human; D054357:Chemokine CXCL10; D006513:Hepatitis B e Antigens